You are here

FDA Approves Desogestrel and Ethinyl Estradiol Tablets

CORONA, Calif., Aug. 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI) , a leading specialty pharmaceutical company, announced today that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application for desogestrel and ethinyl estradiol tablets USP, 0.15mg / 0.03mg, a generic version of Ortho-McNeil's Ortho-Cept(R) and Organon's Desogen(R) products which are indicated for the prevention of pregnancy.

The Company intends to initiate shipments of the product immediately. For the 12-months ending March 2005, desogestrel and ethinyl estradiol tablets USP, 0.15mg / 0.03mg market had total U.S. sales of approximately $180 million, according to IMS Health data.

Source: Watson Pharmaceuticals, Inc.

Recent Headlines

Breast Cancer, Gastrointestinal Tumors Most Common Types
Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens